# EDGAR Filing Document

**Accession Number:** 0001527728
**File Stem:** 0001214659-23-001671
**Filing Date:** 2023-2
**Character Count:** 7936
**Document Hash:** f390c09b13808f898ade4a7ea91f4153
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-23-001671.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001214659-23-001671

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20180216

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Weird Science LLC
- **CENTRAL INDEX KEY:** 0001955760
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38758
- **FILM NUMBER:** 23592197

**BUSINESS ADDRESS:**
- **STREET 1:** 8581 SANTA MONICA BLVD. #317
- **CITY:** WEST HOLLYWOOD
- **STATE:** CA
- **ZIP:** 90069
- **BUSINESS PHONE:** (424)-279-8792

**MAIL ADDRESS:**
- **STREET 1:** 8581 SANTA MONICA BLVD. #317
- **CITY:** WEST HOLLYWOOD
- **STATE:** CA
- **ZIP:** 90069
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enochian Biosciences Inc
- **CENTRAL INDEX KEY:** 0001527728
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 452259340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067
- **BUSINESS PHONE:** 45 39179840

**MAIL ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DanDrit Biotech USA, Inc.
- **DATE OF NAME CHANGE:** 20140214

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Putnam Hills Corp.
- **DATE OF NAME CHANGE:** 20110810

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Weird Science LLC<br><sub>(Last) (First) (Middle)</sub><br>8581 SANTA MONICA BLVD. #317<br><sub>(Street)</sub><br>WEST HOLLYWOOD, CA 90069<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2018-02-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Enochian Biosciences Inc [ ENOB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2018-02-16 |  | J<sup>(1)</sup> |  | 17545283 | A | <sup>(1)</sup> | 17545283 | D |  |
| Common Stock | 2018-12-31 |  | J<sup>(2)</sup> |  | 1268880 | A | <sup>(2)</sup> | 18814163 | D |  |
| Common Stock | 2019-07-30 |  | J<sup>(2)</sup> |  | 3631234 | A | <sup>(2)</sup> | 22445397 | D |  |
| Common Stock | 2020-05-29 |  | J<sup>(3)</sup> |  | 17545283 | D | <sup>(3)</sup> | 4900114 | D |  |
| Common Stock | 2020-12-14 |  | J<sup>(2)</sup> |  | 61249 | A | <sup>(2)</sup> | 4961363 | D |  |
| Common Stock | 2022-04-11 |  | J<sup>(2)</sup> |  | 97032 | A | <sup>(2)</sup> | 5058395 | D |  |
| Common Stock | 2022-04-15 |  | J<sup>(3)</sup> |  | 4961363 | D | <sup>(3)</sup> | 97032 | D |  |
| Common Stock | 2022-10-13 |  | J<sup>(2)</sup> |  | 1216467 | A | <sup>(2)</sup> | 1313499 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger.

(2) Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement.

(3) Pro rata distribution to the members of the Reporting Person.

**Signature:** /s/ William Anderson Wittekind, as Manager  
**Date:** 2023-02-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**